Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...

U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective ...

As an FDA official said that the agency has evidence that links COVID vaccines to the deaths of at least 10 children, the U.S ...

In this morning's Pharmalittle roundup, we're reading about FDA scrutiny of RSV therapies, an AI tool for clinical trials, ...

Health news and commentary gathered by MedPage Today staff ...

FDA turns up the heat: Federal regulators are requesting more safety information from drugmakers on products meant to protect ...

FDA officials are newly scrutinizing several approved therapies to treat RSV in babies despite the fact that these shots were shown to be safe in clinical trials ...

Respiratory syncytial virus, commonly known as RSV, is often associated with cold-like symptoms in young children. But a new ...

In a new study, adults 45 and up who got this seasonal virus had a higher risk of major heart issues, especially in the first ...

Recovering from respiratory syncytial virus often doesn't end when it's time to leave the hospital, even for younger adults.

A new study has found that a significant percentage of adults in the United States have at least one risk factor for severe respiratory syncytial virus (RSV), even as eligibility for the RSV ...

Among adults older adults, a respiratory syncytial virus (RSV) infection increases the risk of cardiovascular events over the ...